Abstract: OBJECTIVE To evaluate the pittsburg sleep quality index (PSQI), sleep dysfunction rating scale (SDRS), self-rating scale sleep (SRSS), athens insomnia scale (AIS), treatment emergent symptom scale (TESS) of estazolam, eszopiclone, zopiclone, mirtazapine, mirtazapine combine with estazolam for insomnia by using the network meta-analysis.METHODS Clinical trials of the medicine mentioned above for insomnia were identified through 4 databases:CNKI, VIP, Wanfang and PubMed (November 2016 ago). The quality of the included trials were assessed using Jadad scores. Data were analyzed with Gemtc 14.3, Stata 13, Review Manager 5.3 software.RESULTS Thirteen studies were included in the analysis. Compared with estazolam, mirtazapine combine with estazolam had lower PSQIWMD=-6.67, 95%CI (-8.38, -4.96), P<0.000 01 and AISWMD=-3.73, 95%CI (-4.51, -2.95), P<0.000 01, zopiclone had lower SDRSWMD=-2.50, 95%CI (-3.71, -1.28), P<0.000 1. Network meta-analysis showed that drugs may be sorted as follows:the sequence of SDRS from high to low were estazolam, eszopiclone, zopiclone; the sequence of AIS from high to low were estazolam, zopiclone, mirtazapine combine with estazolam; the sequence of TESS from high to low were estazolam, zopiclone, eszopiclone.CONCLUSION Estazolam don't show obvious advantages in lower SDRS, AIS, TESS of insomnia. The method of network meta-analysis is efficient in discovering the clinical efficacy and safety of medicine.